secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verve Therapeutics, Inc. (—)
CIK:        0001840574
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055063
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verve Therapeutics reports Q1 2024 net loss of $48.7M; cash runway to late 2026; VERVE-102 first patient dosed
--------------------------------------------------------------------------------

- Net loss of $48.7M ($0.59 per share) vs $52.0M in Q1 2023; R&D expenses $48.4M.
- Cash, cash equivalents, and marketable securities $606.4M; cash runway into late 2026.
- First patient dosed in Heart-2 Phase 1b trial of VERVE-102 (PCSK9); data update expected 2025.
- VERVE-201 (ANGPTL3) Phase 1b initiation on track for H2 2024; completed preclinical studies.
- Received first milestone payment from Eli Lilly for Lp(a) collaboration; total potential milestones up to $465M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/0000950170-24-055063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840574/000095017024055063/verv-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer